Cytokines and pulmonary host defenses

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 2, 1997, Pages 81-88

  Standiford, Theodore J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COLONY STIMULATING FACTOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL PNEUMONIA; HUMAN; IMMUNOLOGY; LUNG; RESPIRATORY TRACT INFECTION; REVIEW;

CHEMOKINES; COLONY-STIMULATING FACTORS; CYTOKINES; HUMANS; INTERFERON TYPE II; INTERLEUKINS; LUNG; PNEUMONIA, BACTERIAL; RESPIRATORY TRACT INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031089947     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199703000-00001     Document Type: Article

References (56)

1. Toews G, Gross, G, Pierce A: The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 1979, 120:559-566.
2. Nelson S, Mason C, Knolls J: Pathophysiology of pneumonia. Clin Chest Med 1995, 16:1-12. An excellent review of cells and cytokines involved in lung innate immunity against bacterial pathogens.
3. Murphy J: Cryptococcosis. In Immunology of the Fungal Diseases. Edited by Cox RA. Boca Raton, FL: CRC Press; 1989:93-138.
4. DesPrez RM, Heim CR: Mycobacterium tuberculosis. In Principles and Practice of Infectious Diseases, edn 3. Edited by Mandell GL, Douglas RG, Bennett JE. New York: Churchill Livingstone; 1990:1877-1905.
5. Laichalk L, Kunkel S, Strieter R, Danforth J, Bailie M, Standiford T: Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun 1996, 64:5211-5218. The first study to demonstrate the effects of in vivo TNF depletion on survival in murine gram-negative bacterial pneumonia.
6. Huffnagle G, Toews G, Burdick M, Boyd M, McAllister K, McDonald R, Kunkel S, Strieter R: Afferent phase production of TNF-α is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996, 157:4529-4536. A well-performed study demonstrating the important role of TNF as a proximal signal in the development of protective immunity to C. neoformans.
7. Tracey K, Beutler B, Lowry S, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 1986, 234:470-474.
8. Le J, Vilcek J: Tumor necrosis factor and interleukin-1: Cytokines with multiple overlapping biological activities. Lab Invest 1987, 56:234-248.
9. Oswald I, Wynn T, Sher A: Interleukin 10 inhibits macrophage microbicidal activity by blocking endogenous production of tumor necrosis factor a required as a costimulatory factor for interferon-γ-induced activation. Proc Natl Aced Sci U S A 1992, 89:6676-8680.
10. Tam A, Ferrante A, Goh D, Robertson D, Cripps A: Activation of the neutrophil bactericidal activity for non typeable Haemophilus influenza by tumor necrosis factor and lymphotoxin. Pediatr Res 1995, 37:155-159.
11. Dehoux M, Boutten A, Ostinelli J, Seta N, Dombret M, Crestani B, Deschenes M, Trouillet J, Aubier M: Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994, 150:710-716.
12. Gosselin D, DeSanctis J, Boule M, Skamene E, Matouk C, Radzioch D: Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun 1995, 63:3272-3278. One of the first studies to demonstrate a role for both TNF and nitric oxide in host immunity against P. aeruginosa.
13. Nelson S, Bagby G, Summer W: Anti-tumor necrosis factor-α antibody suppresses pulmonary anti-bacterial defenses. Am Rev Respir Dis 1991, 143S:393.
14. Brieland J, Remick D, Freeman P, Hurley M, Fantone J, Engleberg N: In vivo regulation of replicative Legionella pneumophila lung infection by endogenous tumor necrosis factor alpha and nitric oxide. Infect Immun 1995, 63:3253-3258. A nice study demonstrating that TNF production in Legionella spp pneumonia is regulated by endogenous nitric oxide.
15. Kolls J, Beck J, Nelson S, Summer W, Shellito J: Alveolar macrophage release of tumor necrosis factor during murine Pneumocystis carinii pneumonia. Am J Respir Cell Mol Biol 1993, 8:370-376.
16. Nelson S: Overview of granulocyte colony-stimulating factor in bacterial infections in the non-neutropenic host. Clin Infect Dis 1991, 143S:398-410.
17. Kolls J, Nelson S, Summer W: Recombinant cytokines and pulmonary host defense. Am J Med Sci 1993, 306:330-335.
18. Preheim L, Snitily M, Gentry M: Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. J Infect Dis 1996, 174:225-228.
19. Lister P, Gentry M, Preheim: Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia. J Infect Dis 1993, 168:922-926.
20. Smith W, Sumnicht G, Sharpe R, Samuelson D, Millard F: Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 1995, 86:1301-1309. One of the first studies demonstrating a beneficial effect of G-CSF administration in gram-negative penumonia complicated by sepsis.
21. Handman E, Burgess A: Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J Immunol 1979, 122:1113-1119.
22. Chen G, Curtis J, Mody C, Christensen P, Armstrong L, Toews G: Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on rat alveolar macrophage anti-cryptococcal activity in vivo. J Immunol 1994, 152:724-734.
23. Mandujano J, D'Souza N, Nelson S, Summer W, Beckerman R, Shellito J: Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice. Am J Respir Crit Care Med 1995, 151:1233-1238.
24. Jenson W, Rose R, Wasserman A, Kalb T, Anton K, Remold H: In vitro activation of the antibacterial activity of human pulmonary macrophages by recombinant gamma interferon. J Infect Dis 1987, 155:574-577.
25. Beck J, Liggitt H, Brunette E, Fuchs H, Shellito J, Debs R: Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun 1991, 59:3859-3862.
26. Skerrett S, Martin T: Intratracheal interferon-γ augments pulmonary defenses in experimental legionellosis. Am J Respir Crit Care Med 1994, 149:50-58.
27. Oppenheim J, Zachariae C, Mukaida N, Matsushima K: Properties of the novel proinflammatory supergene intercrine cytokine family. Ann Rev Immunol 1991, 9:617-647.
28. Huffnagle G, Strieter R, Kunkel S, Toews G, Standiford T: The role of chemokines in pneumonia. In Chemokines in Disease. Edited by Koch A, Strieter R. Austin, TX: R.G. Landis Co; 1996:151-168. A comprehensive review of the role of chemokines in lung antimicrobial host defense.
29. Greenberger M, Strieter R, Kunkel S, Danforth J, Laichalk L, McGillicuddy D, Standiford T: Neutralization of MIP-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 1996, 173:159-165. The first study to establish a causal relationship between C-X-C chemokines and bacterial clearance in pneumonia.
30. + T cells during a pulmonary Cryptococcus neoformans infection. J Immunol 1995, 155:4790-4797. This important study demonstrates the contribution of MCP-1 to cell-mediated immunity in a murine model of cryptococcal pneumonia.
31. Huffnagle G, Strieter R, Standiford T, McDonald R, McNeil LK, Burdick M, Kunkel S, Toews G: Efferent phase production of macrophage inflammatory protein-1α (MIP-1α) is required for protective cell-mediated immunity to a pulmonary Cryptococcus neoformans infection. J Immunol, in press.
32. Brunda M: Interleukin-12. J Leukoc Biol 1994, 55:280-288.
33. Chehimi J, Trinchieri G: Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. Clin Immunol 1994, 14:149-159.
34. Howard M, O'Garra A, Ishida H, Malefyt R, De Vries J: Biological properties of interleukin-10. J Clin Immunol 1992, 12:239-247.
35. Heinzel F, Schoenhaut D, Rerko R, Rosser L, Gately M: Recombinant interleukin 12 cures mice infected with Leischmania major. J Exp Med 1993, 177:1505-1509.
36. Gazzinelli R, Hieny S, Wynn T, Wolf S, Sher A: Interleukin 12 is required for the T-lymphocyte-independent induction of interferon-γ by an intracellular parasite and induces resistance in T-cell deficient hosts. Prac Natl Acad Sci U S A 1993, 90:6115-6119.
37. Wagner R, Steinberg H, Brown J, Czuprynski C: Recombinant interleukin-12 enhances resistance to mice to Listeria monocytogenes infection. Microb Pathog 1994, 17:175-186.
38. Flynn J, Goldstein M, Triebold K, Sypek J, Wolf S, Bloom B: IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995, 155:2515-2524.
39. Stevenson M, Tam M, Wolfeand S, Sher A: IL-12-induced protection against blood-stage Plasmodium chabaudi is requires IFN-γ and TNF-α and occurs via a nitric oxide-dependent mechanism. J Immunol 1995, 155:2545-2556.
40. Kawakami K, Tohyama M, Xie Q, Saito A: IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 1996, 104:208-214.
41. Greenberger M, Kunkel S, Strieter R, Lukacs N, Bramson J, Gauldie J, Graham F, Hitt M, Danforth J, Standiford T: IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996, 157:3006-3012. The first study to determine the role of interleukin-12 in lung antibacterial host defense, as well as the first investigation to employ adenoviral gene therapy in the treatment of infection.
42. Laichalk L, Danforth J, Standiford T: Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Micro 1996, 15:181-187.
43. Cassatella M, Meda L, Bonora S, Ceska M, Constantin G: Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes: evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993, 178:2207-2211.
44. Rolph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min H, In L: IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992, 148:806-814.
45. Kasama T, Strieter R, Lukacs NW, Burdick MD, Kunkel SL: Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994, 152:3559-3569.
46. Howard M, Muchamuel T, Andrade S, Menon S: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993, 177:1205-1208.
47. Standiford T, Strieter R, Lukacs N, Kunkel S: Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995, 155:2222-2229.
48. Greenberger M, Strieter R, Kunkel S, Danforth J, Goodman R, Standiford T: Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995, 155:722-729. The initial study to describe the beneficial effects of in vivo interleukin-10 depletion on bacterial clearance and survival in murine gram-negative bacterial pneumonia.
49. van der Poll T, Marchant A, Keogh C, Goldman M, Lowry S: Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996, 174:994-1000. This investigation provides convincing evidence that interleukin-10 is detrimental to antibacterial host defense, which has important implications in regard to ongoing interleukin-10 immunotherapy trials.
50. Bermudez LE, Champsi J: Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immunol 1993, 61:3093-3097.
51. Davies J: Inactivation of antibiotics and dissemination of resistance genes. Science 1994, 264:375-382.
52. Wunderink R: Ventilator-associated pneumonia. Clin Chest Med 1995, 16:173.23.
53. Nelson S, Farkas S, Fitheringham N, Ho H, Marrie T, Movahhed H: Filgrastim in the treatment of hospitalized patients with community-acquired pneumonia (CAP) [abstract]. Am J Respir Crit Care Med 1996, 153:A535. This recently published abstract provides results from a large multicenter, randomized trial demonstrating beneficial effects of recombinant G-CSF as an adjuvant therapy in patients with severe community-acquired pneumonia.
54. News and Comment: IL-12 deaths: explanation and the puzzle. Science 1995, 270:908.
55. Bramson J, Hitt M, Gallichan W, Rosenthal K, Gauldie J, Graham F: Construction and characterization of an adenovirus expressing IL-12. Hum Gene Ther 1995, 7:333-340.
56. Kolls, J, Lei D, Nelson S, Summer W, Greenberg S, Beutler B: Adenovirus-medlated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis 1995, 171:570-575. This study used a novel technique (adenoviral gene therapy) to neutralize endogenous TNF, which allowed for the assessment of the role of TNF as a mediator of host defense in Pseudomonas spp pneumonia.